Averi Kit
NDC Package 75854-604-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Averi (desogestrel and ethinyl estradiol) kits is aVERI is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.Oral contraceptives are highly effective. This formulation utilizes a kit delivery system. Marketed by Avion Pharmaceuticals, Llc, this product is identified by NDC 75854-604 and is authorized under FDA application ANDA218933.

Identification & Billing

NDC Package Code
75854-604-01
Package Description
1 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
75854060401
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 240707 - desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet
  • RxCUI: 2672922 - ferrous bisglycinate 36.5 MG Oral Tablet
  • RxCUI: 2716396 - {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (ferrous bisglycinate 36.5 MG Oral Tablet) } Pack
  • RxCUI: 2716396 - desogest-eth estra 0.15-0.03 MG (21) Oral Tablet / ferrous bisglycinate 36.5 MG (7) Oral Tablet 28 Day Pack
  • RxCUI: 2716396 - {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (ferrous bisglycinate 36.5 MG Oral Tablet) } 28 Day Pack

Clinical Specifications

Proprietary Name
Averi
Non-Proprietary Name
Desogestrel And Ethinyl Estradiol
Dosage Form
Kit - A packaged collection of related material.
Usage Information
AVERI is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.In a clinical trial with desogestrel and ethinyl estradiol tablets 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. This represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. This rate includes patients who did not take the drug correctly.Table 1: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES.  % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year3  Method(1)Typical Use1(2)Perfect Use2(3)(4) Chance4  85 85  Spermicides5  26 6 40 Periodic abstinence  25  63  Calendar  9   Ovulation Method  3   Sympto-Thermal6  2   Post-Ovulation  1  Withdrawal  19 4  Cap7      Parous Women 40 26 42  Nulliparous Women 20 9 56 Sponge      Parous Women 40 20 42  Nulliparous Women 20 9 56 Diaphragm7  20 6 56 Condom8      Female (Reality®) 21 5 56  Male 14 3 61 Pill  5  71  Progestin Only  0.5   Combined  0.1  IUD      Progesterone T 2.0 1.5 81  Copper T380A 0.8 0.6 78  LNg 20 0.1 0.1 81 Depo-Provera  0.3 0.3 70 Norplant® and Norplant-2®  0.05 0.05 88 Female Sterilization  0.5 0.5 100 Male Sterilization  0.15 0.10 100Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.9Lactation Amenorrhea Method: LAM is a highly effective, temporary method of contraception.10Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998.1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.2Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.4 The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.5 Foams, creams, gels, vaginal suppositories, and vaginal film.6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.7With spermicidal cream or jelly.8 Without spermicides.9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The FDA has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 yellow pills).10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age.AVERI has not been studied for and is not indicated for use in emergency contraception.

Regulatory & Marketing

Labeler Name
Avion Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA218933
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-05-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (75854-604). Click a package code to view its specific billing and regulatory data.

3 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 75854-604-01 identifies a specific commercial package of 1 blister pack in 1 carton / 1 kit in 1 blister pack of Averi, a human prescription drug labeled by Avion Pharmaceuticals, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avion Pharmaceuticals, Llc on June 05, 2025. The current certification is valid through December 31, 2026.

How is this Avion Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 75854060401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
75854-604-01
11-Digit CMS (5-4-2)
75854-0604-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.